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ABSTRACT 
Use of Recombinant Human Granulocyte Colony Stimulating Factor 
as an Adjunct in Antifungal Chemotherapy 
in Various Animal Model Systems 
by 
Lindi Farrell , Master of Science 
Utah State University, 1995 
Major Professor: Dr. Stanley D. Allen 
Department: Animal , Dairy, and Veterinary Sciences 
The growing neutropenic patient population provides an ideal 
target for opportunistic fungal infections. Several effective antifungal 
drugs are toxic at high doses and contraindicated for long-term treatment. 
Recombinant human granulocyte colony stimulating factor (rhG-CSF) has 
been shown to increase neutrophilic numbers and functions , thus 
providing enhanced host defense. Improved efficacy by using rhG-CSF in 
conjunction with various antifungal agents was the primary focus of these 
studies. Use of rhG-CSF in a murine model of vaginal candidiasis did not 
reduce vaginal colony counts, or improve vaginal histopathology scores. 
Administration of rhG-CSF in a murine model of pulmonary aspergillosis 
improved survival, clinical signs, and gross pathology and histopathology 
scores of the lungs, and increased weight gain. The rhG-CSF was not 
shown to be an effective therapeutic treatment in this model of vaginal 
ii 
candidiasis. The rhG-CSF was, however, an effective prophylactic 
treatment in this model of pulmonary aspergillosis. 
(83 pages) 
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INTRODUCTION 
There has been a dramatic increase in the population of 
immunosuppressed patients in recent years. Advances in the treatment of 
cancer, in organ transplantation methods, and in the use of corticosteroids 
have given rise to increased iatrogenic immunosuppression. Infectious 
agents, such as the AIDS virus, also contribute to the growth in this 
population. Many myelosuppressive drugs and diseases of the immune 
system may render the patient severely leukopenic. With a decrease in 
circulating leukocytes, these patients become a target for opportunistic 
infections, which are easily controlled by the immune response in the 
noncompromised host (1 0, 15, 18). 
There are · several effective antifungal antibiotics available for 
treatment of these patients. Amphotericin B (AmB) has been the drug of 
choice for the treatment of invasive mycoses for nearly 30 years. This drug, 
however, is associated with organ toxicity and long-term use is 
contraindicated . Although AmB may be effective in managing fungal 
infection, the host's own immune system is essential for complete clearance 
of some pathogens (2, 22) . 
Current research is providing the medical community with a new 
generation of drugs, biological response modifiers (BRM), and drug delivery 
strategies that are directed at boosting the immune response of the 
compromised host. Granulocyte colony stimulating factors (G-CSF) are 
endogenous granulopoiesis stimulators, and are representative of these 
new drugs. Use of G-CSF stimulates a dose-dependent increase in 
circulating neutrophil counts, and a shift (left) toward earlier granulocyte 
progenitor cells in the circulation. Through recombinant DNA technology, 
human G-CSF has been produced in E. coli in which the human gene for 
G-CSF production has been inserted. Both prophylactic and therapeutic 
treatment with recombinant human G-CSF (rhG-CSF) has been shown to 
decrease the incidence of infection that may be associated with 
myelosuppressive anticancer drugs. Preliminary research indicates that the 
use of rhG-CSF in conjunction with antifungal drugs may also be effective in 
the treatment of opportunistic mycoses. In vivo studies involoving rhG-CSF 
and antifungal drugs are essential in determining the efficacy of such 
treatment modalities (20, 23, 26, 27). 
The objective of these studies was to determine the value of rhG-CSF 
as an adjunct in antifungal chemotherapy using murine models of both 
superficial and systemic mycoses. 
In the first series of studies, both ovariohysterectomized (OVH) and 
nonovariohyserectomized (nonOVH) female mice were treated with 
estradiol valerate in order to induce pseudoestrus. Both OVH and nonOVH 
mice were infected intravaginally with C. albicans to establish a model of 
superficial fungal vaginitis. Groups of nonOVH mice were then 
intravaginally infected with C. albicans and therapeutically treated with rhG-
CSF, using both systemic and topical routes of administration. Clotrimazole 
was administered alone, and in combination with rhG-CSF as comparison 
treatments. Uniform infection and efficacy of treatments were measured 
quantitatively by fungal colony counts. The degree of infection was also 
confirmed by vaginal histopathology. 
In a second series of studies, groups of mice were 
immunosuppressed using cyclophosphamide (CPM). Prophylactic 
2 
treatments with rhG-CSF, liposomal amphotericin B (lip AmB) , AmB, and 
combinations of rhG-CSF and the lip AmB were given. The mice were then 
infected intranasally with A. fumigatus to establish a model of pulmonary 
aspergillosis . The effect of CPM on white blood cell (WBC) counts was 
verified by clinical hemocytology. Animal weights and clinical signs were 
recorded throughout the studies. Efficacy of the treatments was evaluated 
by mean survival times of the various treatment groups, change in animal 
weight, assessment of clinical signs , and gross and microscopic pathology 
of the lungs. 
3 
LITERATURE REVIEW 
Immunosuppression 
The human immune response is a highly complex system regulated 
by both positive and negative feedback mechanisms. The regulatory 
components of this system are capable of being manipulated by many 
factors. The net effect of intrinsic and extrinsic immunoregulation is reflected 
by the state of health and ultimate life span of an individual. In recent years 
there has been a dramatic worldwide increase in the number of both 
iatrogenically and idiopathically immunosuppressed patients being treated 
by the medical community (15,18). 
Technological advances in the treatment of cancer patients have 
increased the number of persons who are iatrogenically 
immunosuppressed. Cytotoxic drugs that are designed to destroy rapidly 
dividing cells are given to these patients to attack cancerous cells. This 
treatment is effective in fighting cancer, but also decreases the effectiveness 
of the host's immune system by reducing the number of proliferating and 
circulating leukocytes available for immune responses. 
Cyclophosphamide is a commonly used, potent immunosuppressive 
agent, capable of inhibiting both humoral and cell-mediated immune 
responses . CPM is indicated for use in patients with malignancies such 
lymphomas, leukemias, neuroblastomas, ovarian carcinomas, carcinoma of 
the breast, and others. It is a synthetic drug that is chemically related to the 
nitrogen mustard family. Studies have shown that relatively short-term CPM 
administration produces immunosuppression by quantitative as well as 
qualitative changes in the lymphocyte populations. Although it is classified 
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generally as an alkylating agent, CPM itself is not an alkylating agent or an 
irritant. It requires activation by a cytochrome system in order to act as an 
alkylating agent. The chloroethyl groups of the activated compound are 
believed to be responsible for its antitumor activity. Alkylation inhibits cell 
division by binding to DNA and causing an abnormal cross linking of the 
DNA strands. This increases the stabil ity of the DNA, rendering it incapable 
of its normal function . Like other nitrogen mustard derivatives, it is absorbed 
from the gastrointestinal tract, metabolized, and distributed throughout the 
body. CPM interferes with the growth of susceptible neoplasms and certain 
normal tissues, but the exact mechanism of its action is unknown (1 ,5,39). 
CPM is commercially available (Cytoxan®, Bristol Meyers Squibb, 
Princeton, NJ). 
Organ transplantation also involves immunosuppression. The 
greatest risk associated with organ transplantat ion is graft rejection . 
Transplant patients are often treated with immunosuppressive drugs in 
order to prevent rejection of the transplanted tissue, which greatly increases 
their susceptibility to disease. 
Patients with autoimmune disorders, such as multiple sclerosis, 
lupus, or arthritis, are often treated with corticosteroids in order to decrease 
the inflammatory response associated with the disease process . This 
treatment decreases the symptoms characteristic of these diseases, but in 
turn, makes these patients likely candidates for infection by decreasing their 
immune response capabilities. 
The rapidly increasing nurnber of patients infected with human 
immunodeficiency virus (HIV) also greatly contributes to the 
immunosuppressed population . The HIV infection drastically reduces, and 
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eventually destroys cellular immunity in its victims , greatly suppressing the 
patient 's ability to combat pathogens, even those that are normally 
nonpathogenic. 
The indiscriminate use of broad spectrum antibiotics and the large 
number of women taking contraceptive medication also contributes to the 
increased incidence of infection, especially those of the urogenital tract. 
These drugs may disrupt the body's protective normal floral populations, 
and leave the patient in a susceptible state of immunosuppression . 
Infections of the urogenital tract may also be exacerbated by factors such as 
pregnancy, diabetes mellitus, or pernicious anemia (13,34). 
Host Resistance and Opportunistic Fungal Infection 
Opportunistic infections are a result of the impairment of host 
immunity, which permits microorganisms of low virulence to cause disease. 
In the immunologically intact host, a wide variety of potential pathogens is 
easily controlled by the host's humoral and cell mediated immune 
responses. Opportunistic fungal infections have become an important 
cause of morbidity and mortality in immunosuppressed patients . 
Candidiasis and aspergillosis are the most common fungal infections in the 
immunocompromised host (15,32). 
Candidiasis. Diseases caused by the several species of Candida 
may include a diverse assortment of conditions ranging from chronic, 
superficial infections of the skin and mucosal surfaces to disseminated 
infections in the severely compromised host. Mucocutaneous infections 
include esophagitis , vulvovaginitis, cystit is , oral thrush , and denture 
stomatitis. Infections of the urogenital tract, which are usually caused by C. 
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albicans, are increasing in frequency. They are found much more 
frequently in females, and may cause inflammation of the vagina and vulva. 
Males may develop balanoposthitis or occasionally urethritis, but are often 
asymptomatic. Systemic infections can include prosthetic valve disease, 
endophthalmitis, hepatosplenic candidiasis, peritonitis, endocarditis, 
meningitis, arthritis, and osteomyelitis (11 ,32). 
The normal host has many defenses against opportunistic candida! 
infections. The skin and mucosal surfaces are very effective barriers against 
microbial invasion. Attachment of C. albicans to vaginal epithelial cells is 
also influenced by the presence of the normal vaginal flora, lactobacilli, 
which may block cellular binding sites and inhibit colonization by potential 
pathogens. In the anestrus vagina, polymorphonuclear leukocytes (PMN) 
are constantly present near the mucosal surface, and phagocytosis of 
invading C. albicans will occur within four to six hours (13 ,35,37) . 
Humoral and cell-mediated immunity are the next line of defense. 
Phagocytosis by neutrophils, eosinophils , monocytes , and other 
macrophage-like cells in the lung and reticuloendothelial system is an 
important part of the host defenses against systemic infection with C. 
albicans. Cutaneous candidiasis is generally associated with conditions 
that alter hydration, pH, or normal flora of the skin and mucosal membranes. 
Primarily superficial disease may also be due to subtle defects in cell-
mediated and other immune defenses that may be seen in patients 
receiving corticosteroids . The disseminated form of candidiasis is usually 
associated with severe defects in the neutrophil defense system, or with 
multiple deficiencies in the host defense system that commonly occur in 
hospitalized cancer patients receiving antimicrobials and cancer 
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chemotherapy. In general, it appears that granulocytopenia or defective 
phagocyte function promotes systemic disease, whereas reduced T cell 
macrophage function promotes mucocutaneous disease (7, 11 ,32,33). 
Aspergillosis . Aspergillus infections can be divided into three 
syndromes. Allergic bronchopulmonary aspergillosis occurs when 
aspergilli colonize the bronchial tree and release antigenic substances that 
cause a hypersensitivity pneumonitis. Aspergillomas (fungus balls) develop 
in pulmonary cavities secondary to other lung disease, such as tuberculosis 
or histoplasmosis. Invasive aspergillosis usually occurs only in the severely 
immunocompromised host , and may be complicated by necrotizing 
tracheobronchitis, rhinocerebral infection, cerebral infarction, and chronic 
destructive granulomatous disease. Parenchymal invasion is often followed 
by angioinvasion , hematogenous dissemination, and often death in the 
severely compromised host . Disseminated aspergillosis occurs in 
approximately one quarter of immunocompromised patients (8, 1 0) . 
The noncompromised host is resistant to pulmonary aspergillosis by 
virtue of the mucociliary escalator system, and circulating and resident 
macrophages of the lungs. The constant ciliary action and associated 
mucous blanket of the upper respiratory tract prevent most potential 
pathogens from ever entering the lungs. Pulmonary alveolar macrophages 
are able to attach to aspergillus conidia that enter the lower respiratory tract, 
even in the absence of antibody or complement. Attachment is followed 
rapidly by phagocytosis, phagolysosomal fusion, and the destruction of the 
resting conidia . Patients with neutropenic disorders or receiving 
neutropenia-inducing chemotherapy drugs become highly susceptible to 
aspergillosis, as the conidia are able to germinate and form hyphae without 
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the threat of phagocytosis, and invade the pulmonary parenchyma 
(6,9, 10,31 ). 
Fungal Pathogenicity 
Pathogenicity is the ability of an organism to cause disease in 
another organism. For an organism to cause disease, it must enter the 
host , multiply in host tissues , resist or not stimulate host defense 
mechanisms, and damage the host. Organismal products that assist in one 
or several of these processes are called virulence factors. Pathogenicity of 
organisms is highly variable depending on both the level of the host 
immune response and the organism's virulence. Both Candida albicans 
and Aspergillus fumigatus are capable of being highly pathogenic in the 
immunodefficient host due to their virulence factors (9,33). 
Candida albicans. Candida albicans, the principal etiologic agent 
in candidiasis, is a member of the comensal flora of the digestive and vaginal 
tracts, but it can manifest as a pathogen in individuals with compromised 
defense mechanisms. These normally inconspicuous comensals can 
multiply on or invade through the mucosal surface to initiate local or systemic 
disease. Mucosal surfaces are the initial site of infection for C. albicans, and 
it is here that the battle between host defenses and microbial pathogenic 
factors occurs (11 ,28). 
Abil ity to adhere to mucosal cells is characteristic of pathogenic C. 
albicans, as compared to some less pathogenic Candida species. The 
ability of C. albicans to form pseudohyphae (also referred to as germ-tubes 
or hyphae in the literature) is associated with increased adherence to human 
epithelial cells , and hence is associated with increased pathogenicity 
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(9,29 ,30,34) . Many physiological changes take place in the vaginal 
epithelium during estrus . These changes may alter the normally protective 
environment and make it more vulnerable to potential pathogens. The 
squamous cell layers become highly keratinized and desquamated. C. 
albicans is capable of utilizing this keratin as a nutrient source. In estrus, the 
mucosa is not accessible to PMN and is highly susceptible to cutaneous 
candidiasis . The hyphae of the organism are able to invade the keratinized 
epithelial cells, and continue to colonize the vagina, outpopulating the 
protective normal flora, and inducing vaginal infection. Recurrent 
vulvovaginal candidiasis is presumed to result from diminished host defense 
mechanisms that increase susceptibility to symptomatic infection, including 
the enhanced conversion of C. albicans from vaginal comensal to pathogen 
(13,34) . 
Aspergillus fumigatus. Aspergilli illustrate particularly well the 
importance of the two factors of pathogenicity, the inherent properties of the 
organisms and the defenses of the individual host. Invasive aspergillosis 
generally occurs in patients with hematological malignancies, neutropenia, 
or other severe derangement of host defense. Suppression of the 
macrophage-neutrophil response enables aspergilli to invade the 
respiratory system of the host (8, 1 0) . 
Aspergillus fumigatus causes the large majority of cases of both 
invasive and noninvasive aspergillosis. They are ubiquitous organisms 
found in soil, water, decaying vegetation, and debris. The conidia are very 
small and easily dislodged and dispersed into the air, allowing susceptible 
hosts to inhale them in large quantities (1 0,31 ). 
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Like many pathogenic fungi , A. fumigatus is capable of 
morphologically transforming into a parasitic hyphal stage under conducive 
conditions. In this infectious stage A. fumigatus form septate hyphae that 
enable them to attach to host cells and invade tissues . The ability of 
aspergilli to enter their infectious hyphal stage at normal body temperature 
also contributes to their pathogenicity. Without adequate host defense, A. 
fumigatus is able to germinate in lung tissue and invade the pulmonary 
parenchyma, inducing aspergillosis (8, 10, 29, 31 ). 
Antifungal Chemotherapy 
Chemotherapeutic management of fungal infections began in 1903, 
when potassium iodide was first used to treat sporotrichosis. The first major 
advance in the search for antifungals was the discovery of a group of drugs 
called the polyenes. Nystatin was first polyene to be used therapeutically. 
Since the introduction of nystatin, a large number of similar antibiotics have 
been reported. Many have proved to be too toxic for clinical use (16). 
Management of candida! infections involves use of nonabsorbable 
antifungal agents, such as nystatin or clotrimazole for mucous membrane 
infection, nystatin ointment for infection of skin and nails, ketaconozole for 
refractory cases of thrush or esophagitis or urinary tract infection, and 
intravenous AmB for patients with fungemia or visceral involvement (33). 
Clotrimazole. Clotrimazole is a broad spectrum antifungal agent 
that inhibits the growth of pathogenic yeasts . Clotrimazole belongs to a 
chemical group known as imidizoles, and exhibits fungicidal activity against 
Candida albicans and other Candida species . It has been postulated that 
the compound affects the permeability characteristics of the membrane, 
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allowing the leakage of essential intracellular components with a 
consequent inhibition of the synthesis of such macromolecules as protein, 
lipid, DNA, and polysaccharides. Clotrimazole is indicated for the local 
treatment of vulvovaginal candidiasis (3) . This product is available without a 
prescription (Gyne-Lotrimin®, Schering-Piough, Memphis, TN) . 
Amphotericin B. The treatment of allergic forms of aspergillosis is 
dependent on inhibiting the immune response elicited by the pathogen, 
whereas the treatment of invasive disease involves aggressive antifungal 
therapy. The treatment of invasive aspergillosis is the nearly always 
intravenous administration of AmB. This is frequently the only effective 
treatment available for potentially fatal fungal disease. In each case , its 
possible life-saving benefit must be balanced against its untoward and 
dangerous side effects. Surgical excision is often indicated in cases 
involving endocarditis, pulmonary aspergilloma, and severe sinusitis 
(16,33) . 
AmB has been the drug of choice for the treatment of invasive fungal 
infections for nearly 30 years. It is a synthetic antibiotic belonging to the 
polyene chemical group, and is fungistatic or fungicidal depending on the 
blood plasma levels achieved and the susceptibility of the infecting fungus . 
The sterols of fungi cell membranes are the target of polyene drugs. These 
compounds act by increasing the cell membrane permeability of sensitive 
fungi , thus provoking leakage of amino acids, sugars, and other metabolites 
from the cytoplasm leading to lysis and cell death. Treatment with AmB is 
highly nephrotoxic because the sterols of mammalian cells are also affected 
by its pharmacokinetic mechanisms. Treatment is indicated primarily for 
patients with progressive, potentially fatal fungal infections (2). AmB is 
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commercially available (Fungizone®, E.R. Squibb, and Sons, Inc., 
Princeton, NJ). 
Liposomal amphotericin B. Current research is providing the 
medical community with improved drug delivery systems that may be 
important in improving the efficacy antifungal agents. Liposomes are 
potentially valuable carrier systems for enhancing the pharmacological 
activity of drugs and the functional incorporation of macromolecules into 
cells. Liposomes are closed spherical vesicles that form due to the 
amphiphilic properties of phospholipids in aqueous solutions. The lipophilic 
properties of AmB allow the drug to be integrated into the lipid bilayer of the 
liposome. The AmB is then administered in a less toxic form, and can be 
given and higher and more prolonged doses with less toxic side effects (25) . 
Liposomal AmB (lip AmB) is an integrated product consisting of the 
antifungal antibiotic AmB, encapsulated in phospholipid vesicles. Lip AmB 
is indicated for use in patients with severe mycoses who fail to respond to 
traditional AmB therapy, have experienced renal nephrotoxity, or have renal 
impairment. Lip AmB is commercially available in several countries in 
Europe (AmBisome®, Vestar, Inc. , San Dimas, CA) . It is currently available 
for compassionate use only in the United States. 
Biological Response Modifiers 
Biological response modifiers (BRM) are agents and treatment 
approaches whose mechanisms of action involve the individual 's own 
biological response. These agents are designed to improve or enhance the 
host's immune response capabilities, rather than relying on exogenous 
agents to combat disease processes. BRM treatment may serve to increase 
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the host's antitumor response, increase tumor cell sensitivity to an existing 
response, decrease maturation or differentiation of tumor cells, or increase 
host tolerance to damage by cytotoxic therapies. The development of BAM 
offers the hope for decreased nonspecific toxicity, which has been a major 
impediment in the development of new chemotherapy drugs. It may be 
even more effective in multitreatment modalities (24,33). 
Colony stimulating factors. One group of BAM is the colony 
stimulating factors (CSF), which are endogenous granulopoeisis 
stimulators . CSF refers to a group of glycoproteins that cause the 
proliferation and differentiation of committed progenitor cells in the 
macrophage-granulocyte cell lineage. Originally it was thought that CSF 
were only cell line stimulators, but it is now widely accepted that they also 
affect the metabolism and function of mature cells. In general, CSF act as 
an enhancer of these cellular functions stimulating metabolic activity, 
increasing protease secretion , and stimulating antitumor and antimicrobial 
activity in mature macrophages (23 ,38). 
Granulocyte colony stimulating factor. Granulocyte colony 
stimulating factor (G-CSF) is an endogenous colony stimulating factor that is 
selective for neutrophil lineage. It is a glycoprotein produced by monocytes, 
fibroblasts, and endothelial cells. G-CSF is not species specific and has 
been shown to primarily affect neutrophil progenitor proliferation, 
differentiation, and selected end-cell functional activation, including 
phagocytotic ability, priming of the cellular metabolism associated with 
respiratory burst, antibody dependent killing , and the increased expression 
of some functions associated with cell surface antigen (12 , 17,38). 
Investigations have indicated that G-CSF is capable of inducing a significant 
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increase in total granulocytes in both normal and granulocyte-macrophage 
deficient individuals, thereby leading to enhanced resistance to microbial 
infections (4, 14, 19). 
Recombinant human granulocyte colony stimulating factor. 
G-CSF can now be produced by recombinant DNA technology. It is 
manufactured in Escherichia coli bacteria in which the human gene for G-
CSF has been inserted. The purified product, recombinant human 
granulocyte colony stimulating factor (rhG-CSF), has a 175 amino acid 
sequence identical to that of the human gene sequence, except for the 
addition of an N-terminal methionine necessary for expression in E. coli. 
Studies using animal models of systemic aspergillosis and candidiasis have 
indicated that the host response mediated by rhG-CSF may be a potent 
stimulus to protect against opportunistic infections. Thus prophylactic 
administration of rhG-CSF to increase natural resistance to infection is 
potentially feasible in high-risk patients (19,20,26,27). 
Filgrastim. The recombinant form of G-CSF is generically named 
filgrastim. Differentials obtained after administration of filgrastim show dose 
dependent increases in white blood cell (WBC) counts, increased 
circulating segmented neutrophils, and increased myeloid:erythroid ratios in 
bone marrow. Filgrastim is indicated to decrease the incidence of infection, 
as manifested by febrile neutropenia, in patients with nonmyeloid 
malignancies receiving immunosuppressive chemotherapy drugs 
associated with a significant incidence of severe neutropenia and fever. 
This drug has been shown to be safe and effective in accelerating the 
recovery of neutrophil counts following a variety of chemotherapy regimens 
(4) . Studies in which patients with advanced malignancies were 
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prophylactically given Filgrastim concluded that the drug reduced the period 
of leukocytopenia after administration of a cytotoxic agent. Such reductions 
in the number of days of neutropenia may prove beneficial both in terms of 
hospital costs, by reducing inpatient care, and in the morbidity and mortality 
of chemotherapy. Use of this BRM may allow physicians to increase the 
dose intensity of cytotoxic drugs, particularly drugs with myelosuppressive 
dose-limiting toxicity at conventional doses (19,23) . Filgrastim is now 
commercially available (Neupogen®, Amgen Inc., Thousand Oaks, CA). 
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MATERIALS AND METHODS 
Vaginal Candidiasis Studies 
Animals and animal care . Twenty-four to twenty-five (24-25) 
gram female ICR mice were obtained (Simonsen Laboratories, Gilroy, CA) . 
The animals were housed in polycarbonate shoebox cages and given ad 
libitum access to a standard laboratory rodent diet and water. 
Fungal strain. Candida albicans SC-9172 clinical isolate was 
obtained from the Squibb Culture Collection (Squibb Corporation, 
Princeton, NJ). 
Induction of pseudoestrus. Pseudoestus was induced by 
estradiol valerate. An injection solution was prepared using a commercially 
available preparation (Delestrogen®, Schein Pharmaceutical, Inc., Phoenix, 
AZ) , which had an estradiol valerate concentration of 40 mg/ml. The stock 
solution of estradiol valerate was diluted using sterile sesame oil to a final 
concentration of 5 mg/ml. Three days prior to challenge with the organism, 
the mice were each given 0.1 ml (0.5 mg estradiol valerate) of the injection 
solution subcutaneously. 
Preparation of challenge inoculum. The C. albicans was 
cultured on Sabouraud dextrose agar (SDA) and isolated colonies were 
picked from the surface of the plate, placed in 10 ml of Sabouraud dextrose 
broth, and allowed to grow for 24 hours at 30°C. After incubation, the broth 
appeared turbid, indicating active growth. One (1.0)-ml aliquots of this broth 
culture were pipetted into a 50-ml flask containing 20 ml of 1% phytone-
peptone and 1% glucose (PPG) solution and the flasks were placed on a 
clinical rotator for 36 hours at room temperature. The contents of each flask 
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were then placed into a conical centrifuge tube and centrifuged at 500 X g 
for 10 minutes. After removal of the supernatant, the pellet was 
resuspended in RPM I 1640 tissue culture medium with 1 000 j.ig/ml of 
streptomycin sulfate and 1000 units/ml penicillin (designated RPM I+) . This 
stock was diluted by serial ten-fold serial dilutions, which were quantified by 
hemocytometer count. The stock suspension of C. albicans was then 
diluted with RPM I+ to a concentration 2.5 x1 07 organisms per mi. This 
inoculum count was again verified by hemocytometer count, and plating of 
serial dilutions on bismuth sulfite-glucose-glycine-yeast (BiGGY) agar, a 
grow1h medium selective for candida species. 
Animal inoculation. The animals were anesthetized with 80 mg/kg 
ketamine hydrochloride by intraperitoneal injection on experiment day zero. 
A 20-1.!1 aliquot of the challenge inoculum was placed in the vagina using a 
22-gauge ball-ended stainless-steel dosing needle. Animals were placed 
in a supine position while anesthetized in order to ensure infection with the 
challenge inoculum. 
Drug preparation . The rhG-CSF was received in 2-ml vials each 
containing 600 Jlg of rhG-CSF. The topical treatment (125 Jlg/ml solution) 
was prepared daily by drawing 0.21 ml of rhG-CSF stock solution into a 
tuberculin syringe. The volume was then increased to 0.5 ml by drawing 
another 0.29 ml of USP DsW. The systemic treatment (25.0 j.ig/ml) was 
prepared daily by drawing 0.083 ml of stock solution of rhG-CSF into a 
tuberculin syringe. The volume was then increased to 1.0 ml by drawing 
another 0.917 ml of USP D5W. 
Clotrimazole and a 1% hydrocortisone preparation (Yeast X®, G.B. 
Fleet Co., Inc., Lynchburg, VA) were used as experimental controls and 
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therapeutic comparisons. Both of the drugs were administered to the 
animals in full strength cream form . 
All compounds were prepared using aseptic technique, and were 
stored at 4°C in the dark in order to ensure drug stability. 
Drug administration . The topical rhG-CSF, clotrimazole, and 
hydrocortisone treatments were administered intravaginally in a 20-1.11 
volume (2 .5 J!g) using a microaliquotor on each treatment day. The 
systemic rhG-CSF treatement was administered in a volume of 0.1 ml (2 .5 
J!g), using a 1-cc insulin syringe b.i.d. on each day of treatment. 
Vaginal cytology. Preliminary studies included validation of a 
murine model of pseudoestrus induced by subcutaneous injection of 
estradiol valerate. On experiment days 0, 3, 5, 7, and 9, the treatment 
groups were sampled and evaluated cytologically to verify pseudoestrus. 
Samples were taken by inserting a sterile urethra-genital calcium alginate 
applicator (Baxter Scientific Products, McGaw Park, IL) dampened in sterile 
phosphate buffered saline (PBS) into the vagina and twisting it several 
times before removal. The swabbage was smeared onto a glass 
microscope slide and allowed to dry for several hours. The slides were then 
stained with Wright's stain for evaluation. 
Microscopic evaluation of estrus cycle stage was based on cellular 
appearance of vaginal sample. Those samples showing nucleated cells 
with well defined borders were determined to be anestrus. Those samples 
showing amorphous, anucleate cells were determined to be in estrus. The 
cycle stages were recorded for individual mice on each day of sampling. 
Quantitative cultures. The vaginas of the infected animals were 
cultured for quantitative evaluation of fungal infection on experiment ·days 1, 
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5, 6, and 7. Mice were anesthetized with 80 mg/kg ketamine hydrochloride 
by intraperitoneal injection. Vaginal epithelial samples were obtained by 
inserting a sterile urethro-genital calcium alginate applicator dampened in 
sterile PBS into the vagina and twisting it several times before removal. The 
swab was then swirled and wrung in 0.4 ml sterile PBS in a 5-ml culture 
tube. The suspensions were diluted ten-fold in sterile PBS. One tenth (0.1) 
ml of each of the dilutions was then spread evenly on BiGGY agar plates 
using a flame-sterilized glass rod. The plates were incubated at 30°C for 48 
hours. Following incubation, those plates showing 30-300 colonies were 
counted and counts were recorded. 
Histopathology. As an experimental endpoint, all animals were 
euthanized with C02. Vaginas were removed and fixed in 10% buffered 
formalin for a minimum of 24 hours. Histology sections were prepared and 
stained with periodic acid Schiff stain (PAS) using standard histology 
methods. Evaluation of epithelial fungal invasion was made 
microscopically. Degree of invasion was graded on a scale of zero to three, 
with zero being minimal organisms present, and three being severe hyphal 
invasion of vaginal epithelium. 
Statistical analysis. The analysis of variance (ANOVA) was 
performed to determine differences in colony count data and histopathology 
scores. The least significant differences (LSD) method was used to 
determine differences between the colony counts of the various vaginal 
candidiasis treatment groups. 
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Pulmonary Aspergillosis Studies 
Animals and animal care . Twenty to twenty-two (20-22) gram 
(Simonsen Laboratories) ICR fBR female mice were used. The animals 
were housed in polycarbonate shoebox cages bedded with dried ground 
corncob. Mice were given ad libitum access to a standard laboratory rodent 
diet and water. After immunosuppression, animals were maintained in 
sterile barrier filter top cages, and were supplied with sterilized bedding, 
feed , and water. 
Immunosuppression. All mice, except those in the control group, 
were administered 200 mg/kg of CPM by subcutaneous injection five days 
prior to day of challenge. 
Fungal strain. Aspergillus fumigatus A TCC 13073 was 
maintained on potato dextrose agar slants at -70°C. The organism was 
transferred to a fresh Sabouraud dextrose agar plate and grown for 13 days 
at 35°C. Spores were harvested and suspended in sterile saline with 0.2% 
Tween 80 and stored at 4°C. 
Drug preparation. The rhG-CSF was received in 2-ml vials with 
each vial containing 600 11g of rhG-CSF. A 25.0-llg/ml solution was 
prepared each day of treatment by drawing 0.083 ml of stock solution of 
rhG-CSF into a tuberculin syringe. The volume was then increased to 1.0 
ml by drawing another 0.917 ml of USP DsW. 
Lip AmB was received as a lyophilized powder in a vial containing 53 
mg of AmB. The powder was reconstituted as per manufacturer's direction 
by adding 12 ml of cold sterile H20 for injection without a bacteriostatic 
agent. Further dilutions with DsW diluent were made to obtain 0.2-ml 
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volumes of the desired levels of dosage. The low dosage was prepared by 
adding 0.12 ml of stock solution to 19.88 ml of diluent; the mid dosage had 
0.23 ml of stock solution in 19.77 ml of diluent, and the high dosage had 
0.45 ml of stock solution in 19.55 ml of diluent. 
AmB was supplied as a lyophilized powder containing 50 mg of 
amphotericin B. The powder was reconstituted as per manufacturer's 
direction using 10 ml sterile water for injection without a bacteriostatic agent. 
The solution was further diluted to 50 IJ.g/ml with D5W. 
All compounds were prepared using aseptic technique, and were 
stored at 4 C in the dark in order to insure drug stability. 
Drug administration. AmB, lip AmB, and DsW were given by 
intraperitoneal injection in a 0.2-ml volume, using a 26-gauge 3/8-inch 
needle and 1-cc syringe. The rhG-CSF was given to the high dosage group 
in a 0.1-ml volume (2.5 Jlg). The low dosage group was given a 0.05-ml 
volume (1.0 IJ.g). Injections were given subcutaneously using a 28-gauge 
1/2-inch needle with a 1-cc insulin syringe. Animals were treated once daily 
for three consecutive days prior to challenge. 
Preparation of challenge inoculum. The inoculum for the 
pulmonary aspergillosis challenge was prepared from spores harvested 
from 13-day-old cultures stored in saline with 0.2% Tween 80. This 
suspension was quantitated by hemacytometer count and diluted with 
saline with 0.2% Tween 80 to make the challenge concentration. The 
challenge inoculum was verified by hemacytometer counts and cultured on 
SDA to verify viable spore counts. 
Animal inoculation. On experiment day zero, the mice were given 
spores intranasally in 60 111 of saline with 0.2% Tween 80 under light sodium 
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pentobarbital anesthesia (55 mg/kg, by intraperitoneal injection) . A 
micropipettor dispensing 20-j.J.I drops was used to deliver three drops to the 
nostrils of each mouse. The mouse was then allowed to inhale the drops. 
In order to maintain body temperature while under anasthesia, the cages 
were placed on electric heating pads until the mice regained 
consciousness. 
Animal survival. A live count of animals was taken daily and 
recorded beginning on the day of pulmonary challenge. The mean survival 
time (MST) of each treatment group was calculated using the number of 
surviving animals on experiment day seven, as no deaths occurred after that 
day. 
Clinical signs. Daily assesment of haircoat condition, posture, and 
and activity level were recorded . Clinical signs were scored on a scale of 
zero to three. Haircoat assessment was based on the condition of the coat. 
A smooth and sleek coat without any roughness noted was given a score of 
zero (normal) . If the coat was roughened or showed divots upon movement, 
it was scored one. If divots were maintained in the coat without movement, it 
was given a score of two. A very rough coat with hair loss noted was scored 
three. 
Posture was scored according to the degree and portion of time the 
mice spent in a hunched position. Mice showing no signs of hunching were 
scored zero (normal) . Mice that hunched only slightly were given a score of 
one. Those that spent a porportionately larger amount of time in a hunched 
position and held their heads down intermittently were given a score of two. 
Mice that maintained a shivering hunched position and held their heads 
down at all times were given a score of three. 
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Activity scores were based on movement in the cages and upon 
handling as the mice were weighed. Escape responses were also 
considered. Mice that were highly active and showed climbing and 
escaping response were graded zero (normal). Mice that showed only 
slightly subdued activity, but still climbed the cage and attempted escape, 
were scored as one. Mice that would only climb about the cage, but did not 
climb or attempt escape, were scored two. Those showing very little motion 
or response were given a score of three. 
Animal weights. Animals were weighed individually at the same 
time of day on each experiment day, and weights were recorded . 
Hemocytology. Preliminary studies included the validation of the 
effects of CPM and rhG-CSF on leukocyte counts. Animals used in this 
study were induced into C02 narcosis, and blood was then drawn via 
cardiac puncture procedure. Animals were then euthanized by cervical 
dislocation. Blood samples were analyzed by the Logan Regional Hospital 
clinical laboratory. 
Gross pathology: Lungs from all animals (except anesthetic or 
dosing deaths) that died prior to sacrifice were retained in formalin. Lungs 
of all remaining animals were removed upon euthanasia with C02. The 
lungs of infected animals were weighed and scored grossly on a scale of 
zero to three. Lungs that appeared normal were scored zero. Lungs 
showing consolidation, hemorrhage, or abcess were scored by degree of 
gross lesion appearance. A lung-body-weight ratio was calculated. 
Histopathology. All lungs from infected animals were fixed in 10% 
buffered formalin and submitted for histopathology with H&E and PAS 
stains. Evaluation of pulmonary fungal invasion was made microscopically. 
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Degree of invasion was graded on a scale of zero to three, with zero being 
few organisms present with little or no invasion, and three being severe 
hyphal invasion of the lung tissue. 
Statistical analysis. Differences in WBC counts, clinical sign 
scores, and gross pathology and histopathology scores were determined by 
ANOVA. The LSD method was used to compare WBC counts and mean 
weights of the various treatment groups. 
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RESULTS 
Validation of a Murine Model of 
Vaginal Candidiasis 
Induction of pseudoestrus. Mice were treated as outlined in 
Table 1 (all tables are located in appendix) . Figure 1 shows the number of 
mice induced into estrus over a period of nine days. Seven days after 
treatment, 100% of mice in the estradiol valerate-treated group were 
determined to be in estrus. Only three out of five (60%) of untreated control 
mice were in estrus by day 5. Four of five (80%) of the estradiol valerate-
treated mice maintained estrus until experiment day 9. These results 
indicate that mice treated with 0.5 mg of estradiol valerate five days prior to 
organismal challenge would be in estrus when inoculated, and would 
maintain estrus for seven days. 
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FIG. 1. Number of estradiol valerate-treated and untreated control mice 
determined to be in estrus from day 0 through 9 days posttreatment. 
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Vaginal candidiasis. Uniform infection in OVH and nonOVH mice 
was verified by vaginal cytology. Mice were infected and treated as outlined 
in Table 2. Quantitative culture results were recorded in Table 3. These 
results indicate that a uniform infection was established in both OVH and 
nonOVH mice by 24 hours after intravaginal inoculation with C. albicans. 
Figure 2 compares the mean log 10/ml of vaginal lavage from both groups 
of mice. Both OVH and nonOVH mice maintained vaginal candidiasis 
infections for seven days, and no significant difference was found between 
quantitative culture results of the two groups (Table 4). 
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FIG. 2. Comparison of colony forming units (log 1 0/ml) in OVH and nonOVH 
mice infected with C. a/bicans. 
PMN migration. The effect of rhG-CSF treatment on PMN 
migration was determined by histopathology. Mice were treated as outlined 
in Table 5. Vagina sections from mice treated both topically and 
systemically with rhG-CSF, as well as untreated control animals, were PAS 
stained and evaluated microscopically. Microscopic remarks were recorded 
in Table 6. Bacterial vaginitis was noted in two of the sections from the 
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systemically treated group of mice. Results indicate that neither topically nor 
systemically administered rhG-CSF caused a demonstrable local increase 
in the number of PMN present in the vaginal mucosa. 
Hemocytology. The effect of rhG-CSF on WBC counts of estradiol-
treated mice was determined by hemocytology. Mice were treated as 
outl ined in Table 7, and WBC counts were recorded in Table 8. Results 
indicate no significant change in WBC count by day of challenge (day 6) in 
mice treated topically with rhG-CSF. The systemic rhG-CSF treatment 
group showed a significant increase in circulating leukocytes by day 6 
(Table 9). The change in WBC counts of the various treatment groups is 
illustrated below in Fig. 3. These results indicate no overt countereffect by 
estradiol treatment on the effect of rhG-CSF on WBC counts. 
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FIG. 3. Effect of topical (2.5 l!g) and systemic (2 .5 l!g) rhG-CSF treatment on 
WBC count of estradiol treated mice. 
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Efficacy of Therapeutic rhG-CSF Treatment 
of Vaginal Candidiasis 
Quantitative cultures. Mice were infected and treated as outlined 
in Table 10. Efficacy of rhG-CSF as a therapeutic treatment of a superficial 
mycotic infection was evaluated by comparison of quantitative cultures from 
the various treatment groups. Cultures were taken on days 1, 5, 6, and 7, 
and recorded in Table 11 . Figure 4 illustrates the quantitative culture results 
of the various treatment groups. No significant reduction in CFU was seen 
in either the systemic rhG-CSF or the topical rhG-CSF treatment groups 
compared to the untreated control group. Clotrimazole alone was effective 
in reduction of CFU, as expected. The combination therapy group also 
showed a significant reduction in CFU in comparison to both the control and 
clotrimazole treatment groups. The comparison treatment with 
hydrocortisone did show a significant reduction in CFU compared to the 
controls, but was the only treatment group that showed a marked increase in 
CFU by on day 7 of the experiment (Table 12). 
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Histopathology. Histological sections of vagina were prepared 
from each of the infected mice and stained with PAS to show fungal 
invasion. The microscopic remarks and fungal invasion scores were 
recorded in Table 13. Differences among the histopathology scores of the 
various treatment groups were found to be significant (Table 14). Sections 
from the systemic rhG-CSF treatment group had an average score of 2.8, 
with severe invasion in four of the five sections of vagina. The topical rhG-
CSF treatment group had an average score of 2.6, also showing severe 
invasion in the majority of the vagina sections. The combination treatment 
group had the lowest average score of 0.6, with the majority of the sections 
showing complete organismal clearance of the vaginal epithelium. The 
hydrocortisone treatment group had an average score of 2.8, with the 
majority of the sections showing severe fungal invasion. 
Validation of Murine Model of 
Pulmonary Aspergillosis 
Immunosuppression . Hemocytology was used to validate the 
leukopenic effect produced by CPM. Mice were treated as outlined in Table 
15. WBC counts of the of the treatment groups were recorded in Table 16. 
Figure 5 illustrates the change in WBC count from five days prior to 
challenge (day -5) through day of challenge . The WBC count of mice 
treated with CPM decreased from 6.5 X 1 03 to 2.1 X 103 within 24 hours of 
injection. On day 0 (day of challenge) WBC counts of CPM treated mice 
were significantly lower than the immune normal mice (Table 17). 
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lmmunostimulation. The stimulatory effect of rhG-CSF on WBC 
count of leukopenic and normal mice was determined by hemocytology. 
Animals were treated as outlined in Table 15. Figure 6 shows the change 
in WBC count from five days prior to challenge to day of challenge as 
recorded in Table 16. On day 0 (day of challenge) animals treated only with 
CPM had an average WBC of 2.6 X 103. Those mice treated with CPM and 
rhG-CSF had a significantly higher average WBC count of 13.4 X 1 03. 
Immune normal mice, receiving only rhG-CSF treatment, had an average 
WBC count of 23.0 X 103. This was significantly higher than either the 
CPM-treated or untreated control mice (Table 17). 
Efficacy of Prophylactic rhG-CSF Treatment 
of Pulmonary Aspergillosis 
Efficacy of rhG-CSF as a prophylactic treatment in murine pulmonary 
aspergillosis was determined by animal survival, change in weight, daily 
assessment of clinical signs, and gross pathology and histopathology. 
Animal survival. Mice were treated as outlined in Table 18. Figure 
7 compares the MST of the various treatment groups for experiment days 0-
7, calculated from survival data recorded in Table 19. The low rhG-CSF, 
low lip AmB, both combination treatment groups, and the toxicity control 
group had MST of 7.0 days (100% survival). Animals treated with AmB 
survived for an average of 6.5 days. The mid and high lip AmB treatment 
groups had MST of 6.1 and 5.3 days, respectively. The untreated control 
group had the lowest MST of 2.9 days. No deaths were observed on 
experiment days 8 - 20. 
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FIG. 5. Effect of 200 mg/kg dose of CPM (day -5) on average WBC count vs. 
untreated control group. 
Change in Average WBC Count 
25 
0 
0 
:;! 
20 
X 
'E 
----a- Control 
:I 15 0 - CPM/rhG·CSF 
0 
- CPM 
0 10 Ill 
- rhG-CSF ;,:: 
., 
"' 
5 !.'! 
., 
> 
< 0 
- 5 -4 - 3 -2 - 1 0 
Days Prior to Challenge 
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FIG. 7. Mean survival time of treatment groups, experiment days 0-7. 
Change in weight. Animal weights were recorded daily 
beginning six days prior to challenge in Tables 20 and 21 . Figures 8-11 
show the change in weight of various treatment groups compared to the 
untreated control group, which gained an average of 1.2 grams over the 26-
day period. The low and high rhG-CSF treatment groups showed the 
greatest weight gain with averages of 5.9 and 6.1 grams, respectively. All 
treatment groups showed significant weight gain in comparison to the 
control group, except for the AmB treatment groups (Table 22) . 
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FIG. 8. Change in weight of 1.0 ~g and 2.5 ~g rhG-CSF treatment groups 
vs. the untreated control group. 
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FIG. 9. Change in weight of 5 ~g. 10 ~g. and 20 ~g lip AmB treatment 
groups vs. the untreated control group. 
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Change in Weight: AmB Treatment 
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FIG. 10. Change in weight of AmB treatment group vs. the untreated control 
group. 
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FIG. 11. Change in weight of 1.0 1.19 rhG-CSF/1 0 llg lip AmB group and 
2.5 1.1g rhG-CSF/1 0 1.19 lip AmB group vs. the untreated control group. 
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Assessment of clinical signs. Clinical signs, including haircoat 
condition , animal posture, and level of activity, were scored daily and 
recorded in Table 20. 
Figures 12-15 show the average daily assessment score for haircoat 
condition of the various treatment groups. Variation among the haircoat 
scores of the various treatment groups was found to be significant (Table 
23) . The untreated control group had an overall average haircoat score of 
1.8. The low and high rhG-CSF groups had average haircoat scores of 1.1 
and 1.3, respectively. Mice treated with low, mid, and high lip AmB doses 
had average scores of 1.4, 1.6, and 1.8, respectively. AmB-treated mice had 
a mean score of 1.2. The low combination group scored 1.2, and the high 
combination group scored 1.4 in haircoat assessment. The toxicity control 
group had an average haircoat score of 0.9. 
Average daily assessment scores for posture of the various treatment 
groups is shown in Figs. 16-19. Variations among average posture scores 
of the various treatment groups were found to be significant (Table 24) . Low 
and high rhG-CSF treatment groups averaged 0.8 and 0.9, respectively, in 
posture assessment. The low, mid, and high lip AmB treatment groups 
averaged 0.9, 0.8, and 1.2, respectively. The mean posture assessment 
score for the AmB treatment group was 0.8. The low and high combination 
treatment groups both averaged 0.8 in posture assessment. The toxicity 
control group had an average posture score of 0.6. 
Average daily assessment scores for activity level of the various 
treatment groups are shown in Figs. 20-23. Variation in activity scores 
among various treatment groups was found to be significant (Table 24) . 
The untreated control group had an average activity score of 1.0. The low 
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Haircoat: rhG-CSF Treatments 
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FIG. 12. Average daily haircoat assessment score for 1.0 !lg and 2.5 !lg 
rhG-CSF treatment groups vs. untreated control group. 
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FIG. 13. Average daily haircoat assessment score for 5.0 !lg, 10.0 !lg, and 
20.0 !lg lip AmB treatment groups vs. the untreated control group. 
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FIG . 14. Average daily haircoat assessment score for 20.0 11g AmB 
treatment group vs . the untreated control group. 
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FIG . 15. Average daily haircoat assessment score for 1.0 11g rhG-CSF/10.0 
11g lip AmB, and 2.5 11g rhG-CSF/1 0.0 11g lip AmB treatment groups vs. the 
untreated control group. 
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Posture: rhG-CSF Treatments 
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FIG. 16. Average daily posture assessment score for 1.0 jJ.g and 2.5 jJ.g 
rhG-CSF treatment groups vs. the untreated control group. 
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FIG. 17. Average daily posture assessment score for 5.0 IJ.g, 10.0 jlg, and 
20.0 IJ.g lip AmB treatment groups vs. the untreated control group. 
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FIG. 18. Average daily posture assessment score for 20.0 11g AmB treatment 
group vs. untreated control group. 
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FIG. 19. Average daily posture assessment score for 1.0 11g rhG-CSF/10.0 
11g lip AmB, and 2.5 11g rhG-CSF/1 0.0 11g lip AmB combination groups vs. 
the untreated control group. 
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and high rhG-CSF treatment groups had average sores of 0.7 and 0.6, 
respectively. The low, mid, and high lip AmB groups had average scores of 
0.7, 0.4 , and 1.0, respectively. The AmB-treated group had an average 
score of 0.7 The low and high combination groups both had average 
activity assessment scores of 0.6. The toxicity control group had an average 
activity score of 0.4. 
Gross pathology. Gross pathology scores (GPS) of lungs and 
lung-body-weight ratios (LBWR) of infected and control mice were recorded 
in Table 26. The untreated control group had a LBWR of 0.011 , and the 
highest GPS of 1.5. The low combination treatment group had the lowest 
LBWR of 0.008, and the lowest GPS of 0.1. The high rhG-CSF treatment 
group had a LBWR of 0.009 and a GPS of 0.3. A higher LBWR was 
suggestive of a greater amount of lung consolidation, but was not directly 
correlated , as there are no standards available. No statistically significant 
differences were found between the GPS of the various treatment groups 
compared to the control score (Table 27) . 
Histopathology. Representative sections of lung were taken from 
infected animals, and stained with PAS in order to evaluate fungal invasion 
of the tissue. The histopathology scores (HPS) were recorded in Table 26. 
Although the scores were not found to be significantly different, there were 
obvious trends noted among the lung scores of the various treatment groups 
(Table 28) . The untreated control group had an average score of 1.5. There 
were only two animals remaining in this group. One animal had severe 
invasion, and the other had few organisms present. The low dosage rhG-
CSF group had a lower mean score of 0.9, with the majority of the animals 
having little or no fungal invasion, and some consolidation. The high rhG-
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CSF dosage group had the lowest average score of 0.8 , with little or no 
invasion and only mild consolidation in most of the lungs. The low lip AmB 
dosage group averaged 1.9. This group ranged from few organisms seen to 
severe invasion with most of the lungs showing walled off areas of 
organismal invasion. The mid lip AmB treatment group had a mean score of 
2.1. The majority of the lungs in this group showed severe invasion, and 
notable consolidation and necrosis. The high lip AmB dosage group had 
the highest average score of 2.4 . Most of the lungs showed severe 
parenchymal invasion, and consolidation and necrosis throughout the 
sections. The AmB treatment group scored 2.1 in degree of invasion. The 
lungs of this group ranged from few organisms to severe fungal invasion. 
There was notable consolidation and necrosis in the majority of the lungs, 
with walled off areas of organisms in several of the sections. The low dose 
combination group had an average score of 1.3. Only one animal showed 
severe invasion. The majority of the sections showed minimal to moderate 
invasion, with areas of walled off organisms in most of the sections. The 
high combination group had a mean score of 1.2. The invasion was mostly 
minimal , with only one section showing severe invasion. There was only a 
moderate amount of consolidation noted, and few areas of walled off 
organisms. 
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FIG. 20. Average daily activity level assessment score for 1.0 11g and 2.5 11g 
rhG-CSF treatment groups vs. the untreated control group. 
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FIG. 21 . Average daily activity level assessment score for 5.0 11g, 10.0 11g, 
and 20.0 11g lip AmB treatment groups vs. the untreated control group. 
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FIG. 22. Average daily activity level assessment score for 20.0 11g AmB 
treatment group vs . the untreated control group. 
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FIG. 23. Average daily activity level assessment score for 1.0 11g rhG-
CSF/10.0 J.l.g lip AmB and 2.5 J.l.g rhG-CSF/10.0 jlg lip AmB combination 
groups vs. the untreated control group. 
44 
DISCUSSION 
The use of biological response modifiers , such as rhG-CSF, as 
adjuncts in the treatment of fungal infection has been shown by Mayer et al. 
to reduce the incidence of infection and decrease the recovery time of 
neutropenic patients (20) . The purpose of these studies was to validate 
murine models of superficial and deep mycoses, and to demonstrate the 
efficacy of rhG-CSF as a therapeutic treatment in vaginal candidiasis , and 
as a prophylactic treatment of pulmonary aspergillosis. 
Vaginal candidiasis is a chronic or recurrent superficial mycosis in 
both immunosuppressed and immune normal females. The establishment 
of a cost -effective murine model of vaginitis allows for research in the 
treatment of this infection. It has been demonstrated that a well developed 
stratum corneum, analogous to human epidermis, was present in the mouse 
vagina only during estrus (35) . It is therefore necessary to induce 
pseudoestrus in order to establish a model of vaginal candidiasis. Sixty 
percent of mice administered 0.5 mg of estradiol valerate were cytologically 
determined to be in estrus three days after injection. By five days after 
injection, 100% of the estradiol treated mice were found to be in estrus 
stage, compared to only 60% of untreated control mice. All estradiol-treated 
mice maintained estrus for seven days after injection. These results 
validate the pseudoestrus model , and indicate that all mice would be in 
estrus stage at the time of organismal challenge (experiment day 3) . By 
repeating estradiol injections on a weekly schedule, continuous estrus 
could be maintained. 
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Ovariohysterectomized animals have generally been used in models 
of vaginal candidiasis , so that the hormonal effect of the ovaries would not 
interfere with the induction of pseudoestrus . Using intact mice is more time 
and cost-effective than using surgically altered mice. Both OVH and 
nonOVH mice infected intravaginally with 2.5 X 107 org/ml suspension of C. 
albicans maintained vaginal infections for seven days after organismal 
challenge . These results indicate that a single 0.5-mg injection of estradiol 
valerate completely overrides the effect of the ovaries in intact mice. 
Treatment with antifungal agents, such as clotrimazole, is highly 
effective in controlling vaginal candidiasis infections, but is ineffective in 
preventing recurrent infection. The use of endogenous BRM in conjunction 
with commercially available antifungals may improve the efficacy of 
treatment. The main host defense mechanism in fighting localized 
candidiasis is thought to be based on cell-mediated immunity, and not 
neutrophilic response as indicated by Polak-Wyss . As was expected, no 
improvement was seen in the treatment of vaginal candidiasis with 
systemically or topically administered rhG-CSF alone, which enhances only 
the granulocytic defense mechanisms (27) . There was no reduction in 
colony counts compared to the control group, and no histopathological 
improvements were noted in the vaginas of the rhG-CSF-treated mice. 
However, when rhG -CSF was used in combination therapy with 
clotrimazole, a reduction in vaginal colony counts was noted. A single 
mouse in this treatment group showed complete organismal clearance on 
culture days 5, 6, and 7 (Table 11). These unusual data points indicate the 
need for further studies in the treatment of vaginal candidiasis with rhG-CSF 
in combination with clotrimazole. 
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Deep mycoses, such as pulmonary aspergillosis , are increasingly 
common in neutropenic patients . The neutropenic effects of either 
iatrogenic or idiopathic immunosuppression predisposes patients to 
infection with normally nonpathogenic organisms. It has been 
demonstrated that a neutropenia of the same magnitude, which is critical in 
human resistance, is induced in mice with a single 200-mg/kg dose of CPM 
(20 ,26) . Similar results were obtained in our murine model of 
immunosuppression. Mice administered CPM five days prior to organismal 
challenge had a substantial decrease in average peripheral leukocyte 
counts , compared to the untreated control mice. These mice would then be 
more susceptible to infection with A. fumigatus than the immune normal 
mice. 
The administration of rhG-CSF has been shown to reverse the 
neutropenic effect of cytotoxic drugs, thus providing the host with enhanced 
protection against infection. A comparison of change in WBC counts in 
normal and CPM immunosuppressed mice treated with rhG-CSF confirmed 
results of both Mayer and Polak-Wyss. Immune normal mice treated with 
rhG-CSF, showed a marked increase in WBC within 24 hours of injection. 
The mice immunosuppressed with CPM, and then subsequently treated with 
rhG-CSF, demonstrated a WBC count rebound effect evident within 72 
hours of injection (Fig. 6) . Both groups of mice would have a higher WBC 
count than those treated only with CPM at the time of organismal challenge. 
These results demonstrate the stimulatory effect of rhG-CSF on WBC counts 
of both immune normal and immunocompromised mice (20,26) . 
Amphotericin B has been the drug of choice in the treatment of deep 
mycoses for nearly 30 years . Although this drug is highly effective, the 
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associated toxicity of AmB is often an important issue in the treatment of 
seriously ill patients. The development of improved drug delivery systems 
may increase the therapeutic index of some commonly used antifungal 
agents that are toxic to the patient. Liposomal AmB has been shown to be 
less toxic than AmB, and able to attain higher serum levels at similar doses 
(21 ,22). Our studies did not demonstrate improved efficacy in treatment of 
pulmonary aspergilllosis using lip AmB in comparison to AmB. No increase 
in MST or weight gain was seen in the lip AmB-treated groups when 
compared to the AmB group. The average clinical signs of AmB-treated 
mice were comparable to those treated with lip AmB. No notable 
differences were seen in the gross pathology scores or histopathology 
scores of the two groups. 
The results from the three dosage level groups of lip AmB-treated 
mice imply that there is a toxic effect with increasing dosage. Intraperitoneal 
injection of lip AmB was shown by Moonis et al. to result in lower tissue 
concentrations than when injected intravenously. These findings explain 
the high gross pathology and histopathology scores of the lip AmB groups, 
as there would be a lower concentration of the drug in the lungs at the time 
of challenge, allowing for increased fungal invasion of tissues. It has also 
been shown by Moonis and Mehta that macrophages play an important role 
in the transport of lip AmB to the site of infection. Depletion of granulocytic 
phagocytes by immunosuppression increases the virulence of aspergillosis, 
as well as the toxicity of lip AmB (21 ,22). Lower MST, decrease in weight 
gain, and higher clinical sign scores seen with increased dosage of lip AmB 
support these possible mechanisms for increased lip AmB toxicity. 
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The administration of rhG-CSF has been shown to have a protective 
effect on immunosuppressed mice infected with A. fumigatus (20,27,36) . 
Our studies showed improvement in all experimental monitors and 
endpoints of animals treated prophylactically with rhG-CSF, and 
combinations of rhG-CSF and lip AmB. Both dosage levels of rhG-CSF 
showed increased MST and weight gain in comparison to the untreated 
controls . A more rapid decrease in untoward clinical signs was also noted 
in those animals treated with rhG-CSF. Both gross pathology and 
histopathology of lungs revealed fewer organisms, and less consolidation 
and necrosis than seen in the lungs of any of the other treatment groups. 
Our studies confirm the protective effect of prophylactic rhG-CSF treatment 
against pulmonary aspergillosis . 
Potential toxicity of rhG-CSF and lip AmB combination therapy was 
addressed by the inclusion of an unchallenged toxicity control group. This 
treatment group had a 100% survival rate, and had an average weight gain 
comparable to that of the challenged combination therapy groups. The 
toxicity group exhibited lower clinical sign scores than any other treatment 
group. These results indicate that there is no overt toxicity or counteractive 
effect in the combination therapy dosage used. 
In conclusion, it does not appear that rhG-CSF is effective in the 
treatment of this murine model of vaginal candidiasis when administered 
alone, either systemically or topically. Combination therapy with rhG-CSF 
and clotrimazole reduced colony counts in infected mice. Further research 
is needed to confirm these data. Our results indicate that rhG-CSF is 
effective in the prophylactic treatment of pulmonary aspergillosis when 
administered alone, or in combination with lip AmB. 
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Opportunistic fungal infections continue to be a growing problem in 
the medical community today. Technological advances have provided the 
medical community with improved methods of cance r treatment, 
autoimmune disease management, and organ transplantation . These 
advances, however, have provided many normally nonpathogenic 
organisms, such as C. albicans and A. fumigatus, an opportunity to infect 
the immunocompromised host with potentially fatal diseases. The AIDS 
epidemic, with no cure foreseen in the near future, will also continue to be a 
factor in the fight against these infections. This group of diseases will 
continue to plague patients unless alternate treatment modalities are 
developed. Research focused on developing biological response modifiers, 
rather than exogenous antimicrobial agents, may be the key to fighting 
some opportunistic infections. Drugs aimed at enhancing host immunity, 
rather than controlling the infecting organism, could provide the host with 
the defenses needed to eradicate infecting pathogens. In vivo animal 
research of efficacy, toxicity, and combination therapy provides the medical 
community with important data for use in human clinical trial design. 
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APPENDIX 
TABLE 1. Validation of a murine model of vaginal candidiasis: Effect of 
estradiol valerate on vaginal cytology 
Box #of Pseudoestrus Monitor 
mice Treatment 
181 5 None vaginal smears 
histopatholo~w sections 
182 5 Estradiol valerate vaginal smears 
0.5 mg histopathology sections 
TABLE 2. Validation of a murine model of vaginal candidiasis: Effect of 
intravaginal challenge with C. albicans in nonOVH and 
OVH mice 
Box #of Challenge Mouse Pseudoestrus Monitor 
mice Concentration Treatment 
169 6 2.5 X 107 nonOVH Estradiol valerate Colony 
org/ml 0.5 mg counts 
170 6 2.5 X 107 OVH Estradiol valerate Colony 
org/ml 0.5mg counts 
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TABLE 3. Validation of a murine model of vaginal candidiasis: Quantitative 
culture results of OVH and nonOVH mice 
CFU log10/ml 
Mouse Da 
0 1 5 6 7 
A 4.69 5.39 5.46 5.12 
B 5.03 5.95 5.48 5.21 
Box 169 c 5.39 5.48 5.48 5.18 
nonOVH D 4.79 5.44 4.95 5.11 
E 5.21 5.07 4.92 4.95 
F 4.86 5.75 5.56 5.21 
Average 4.99 5.51 5.31 5.13 
stand. dev. 0.27 0.30 0.29 0.10 
A 4.14 4.77 4.97 5.05 
B 4.65 6.1 0 5.73 5.50 
Box 170 c 4.80 6.31 6.35 5.57 
OVH D 5.05 5.92 6.12 5.56 
E 4.74 5.74 5.79 4.62 
F 4.78 6.00 5.52 5.29 
Average 4.69 5.81 5.75 5.27 
stand . dev. 0.30 0.54 0.48 0.37 
TABLE 4. Validation of a murine model of vaginal candidiasis: Statistical 
analysis of quantitative culture results of OVH and nonOVH 
mice 
Analysis of Variance 
Source df ss MS F value p value 
treatment 1 0.0230 0.0230 0.093 >0.75 
error a 10 2.4690 0.2469 
day 3 4.8128 1.6043 25.164 <0.0005 
error b 15 0.9568 0.0638 
interaction 3 0.6877 0.1959 4.073 0.03 
error c 15 0.7221 0.0481 
Total 47 9.5714 9.5714 
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TABLE 5. Validation of a murine model of vaginal candidiasis: The effect of 
topical and systemic treatment with rhG-CSF on PMN migration 
Box #of Pseudoestrus Treatment Monitor 
Mice Pretreatment 
183 5 Estradiol valerate Topical rhG-CSF Histopathology 
0.5 mg 2.5 Jlg 
184 5 Estradiol valerate Systemic rhG-CSF Histopathology 
0.5 mg 2.5 1!9 
185 5 Estradiol valerate Control animals Histopathology 
0.5 mg no treatment 
TABLE 6. Validation of a murine model of vaginal candidiasis: 
Vaginal histopathology of mice treated with rhG-CSF 
Box Treatment Microscopic Remarks 
Topical Normal vaginal epithelium with cornification 
183 rhG-CSF indicative of estrus staQe in all 5 sections. 
Systemic Cornified vaginal epithelium, showing bacterial 
184 rhG-CSF vaginitis in 2 sections, with some inflammatory 
cell infiltration. 
Untreated Normal vaginal epithelium with cornification, 
185 Control foci of inflammation in one section. 
TABLE 7. Validation of a murine model of vaginal candidiasis: The effect 
of topical and systemic rhG-CSF treatment on WBC count of 
mice treated with estradiol valerate 
Box # Pseudoestrus Treatment Monitor 
mice 
449 40 None Control WBC count 
No treatment Days 1 ,3,5,6 
186 40 Estradiol valerate Systemic rhG-CSF WBC count 
0.5 mg 2.5 Jlg Days 1 ,3,4,5,6 
187 16 Estradiol valerate Topical rhG-CSF WBC count 
0.5 mQ 2.5 !l!=l Days 1, 6 
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TABLE 8. Val idation of a murine model of vaginal candidiasis: WBC counts 
of mice treated topically and systemically with rhG-CSF 
WBC X 103/ ml 
Treatment Ex Jeriment Day 
GrouQ_ 1 3 4 5 6 
7.9 8.8 7.7 4.9 
3.9 6.8 7.4 4.1 
Box 449 5.7 6.4 5.4 4.9 
Control 6.8 5.7 6.4 5.0 
No Treatment 5.0 6.0 8.0 5.9 
5.1 7.3 5.9 5.9 
4.3 7.6 7.2 7.3 
6.0 7.5 7.3 6.0 
Average WBC 5.6 7.0 ND 6.9 5.5 
7.9 7.5 
3.9 8.1 
Box 187 5.7 11.0 
Topical 6.8 8.6 
rhG-CSF 5.0 6.1 
5.1 9.0 
4.3 9.7 
6.0 8.8 
Average WBC 5.6 ND ND ND 8.6 
7.9 7.9 15.1 13.3 30.5 
3.9 7.0 19.9 14.0 21.4 
Box 186 5.7 9.3 13.4 21.7 28.4 
Systemic 6.8 11 .6 13.9 14.4 15.9 
rhG-CSF 5.0 10.2 13.1 11 .5 22.1 
5.1 7.8 15.7 19.5 22.1 
4.3 7.5 17.3 21.4 12.1 
6.0 8.7 20.2 26.2 9.8 
Avera~e WBC 5.6 8.9 16.1 17.8 20.3 
ND = No data collected on these days. 
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TABLE 9. Validation of a murine model of vaginal candidiasis: Statistical 
analysis of WBC count data from day 6 
Analy_sis of Variance 
Source df ss MS F value p value 
treatment 2 973.0 486.5 25.81 0.000 
error 21 395.8 18.8 
Total 23 1368.8 
Mean Comparison LSD-2.080 
Treatment D<!Y Number Mean Difference Significant 
Control 6 8 5.500 
Systemic 6 8 20.288 14.700 . 
Topical 6 8 6.800 1.300 
. . . WBC count s1gn1f1cantly different than untreated control group . 
TABLE 10. Efficacy of therapeutic treatment with rhG-CSF in a murine 
model of vaginal candidiasis: Experimental design 
Box #of Challenge Treatment Monitor 
mice Concentration 
171 5 2.5x1 0 7 org/ml Control colony counts 
No treatment 
172 5 2.5x1 o7 org/ml Systemic rhG-CSF colony counts 
2.5 !lg histopathology 
173 5 2.5x1o7org/ml Topical rhG-CSF colony counts 
2.5 llg histopathology_ 
174 5 2.5x1 o7 org/ml Clotrimazole colony counts 
20 Ill 
175 5 2.5x1 o7 org/ml Clotrimazole 20 111 & colony counts 
Systemic rhG-CSF 2.5 1.1g histopathology 
176 5 2.5x1o7org/ml Hydrocortisone colony counts 
20 Ill histopathology 
177 5 None Control histopathology 
No treatment 
178 5 None Topical rhG-CSF histopathology 
2.5 llg 
179 5 None Clotrimazole histopathology 
20 Ill 
180 5 None Clotrimazole 20 111 & histopathology 
Systemic rhG-CSF 2.5 11g 
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TABLE 11 . Efficacy of therapeutic treatment with rhG-CSF in a murine 
model of vaginal candidiasis: Quantitative culture results 
Treatment CFU log1 o/ml 
Group Da~ 
0 1 5 6 7 
A 4.41 5.47 5.51 5.63 
Box 171 B 4.41 5.67 5.53 5.58 
No Treatment c 5.12 5.43 5.61 5.53 
D 4.79 5.08 5.07 3.55 
E 4.53 5.30 5.17 4.41 
Average 4.65 5.39 5.38 4.94 
stand. dev. 0.30 0.22 0.24 0.93 
A 4.59 6.00 5.52 5.49 
Box 172 B 5.01 5.66 5.26 5.55 
Systemic c 4.67 4.99 5.15 5.05 
rhG-CSF D 4.48 6.05 5.87 5.44 
E 5.39 5.68 5.36 5.22 
Average 4.83 5.68 5.43 5.35 
stand. dev. 0.37 0.42 0.28 0.21 
A 4.51 5.28 4.70 4.46 
Box 173 B 4.29 5.23 4.96 4.95 
Topical c 5.14 5.32 4.07 3.99 
rhG-CSF D 4.54 5.27 4.95 4.38 
E 4.99 5.41 5.39 5.26 
Average 4.70 5.30 4.81 4.61 
stand. dev. 0.36 0.07 0.48 0.50 
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TABLE 11 . Continued 
Treatment CFU log10/ml 
Group Day 
0 1 5 6 7 
A 4.55 3.41 3.17 4.71 
Box174 B 4.53 2.71 3.29 2.68 
Clotrimazole c 5.08 2.71 2.24 1.80 
D 4.63 3.09 3.62 2.96 
E 4.97 4.14 3.32 3.14 
Average 4 .75 3.21 3.13 3.06 
stand. dev. 0.25 0.60 0.52 1.05 
A 5.83 0.0 0.0 0.0 
Box 175 B 5.04 3.35 3.15 2.71 
Clotrimazole & c 4.31 4.07 3.16 2.99 
Systemic D 4.95 1.80 2.83 3.04 
rhG-CSF E 4.64 3.11 2.10 3.63 
Average 4.95 2.31 2.25 2.47 
stand. dev. 0.57 1.81 1.33 1.42 
A 4.45 4.63 4.50 4.70 
Box 176 B 4.60 4.09 4.20 4.79 
Hydrocortisone c 4.72 3.97 3.11 3.65 
D 4.71 5.12 4.34 4.45 
E 4.51 4.73 3.27 4.51 
Average 4 .60 4.51 3.88 4.42 
stand. dev. 0.12 0.48 0.64 0.45 
TABLE 12. Efficacy of therapeutic treatment with rhG-CSF in a murine 
model of vaginal candidiasis: Statistical analysis of 
quantitative culture results 
Analysis of Variance 
Source df ss MS F value p value 
treatment 5 83.3783 16.6757 19.159 <0.0005 
error a 24 20.8887 0.8704 
day 3 7.9523 2.6508 12.445 <0.001 
error b 12 2.5557 0.2130 
interaction 15 33.3215 2.2214 5.984 <0.0005 
error c 60 22.2732 0.3712 
Total 119 170.3679 
Mean Comaparison LSD-0.6089 
Treatment Day N Mean Difference Significant 
Control 1 ,5,6,7 20 5.0900 
Systemic rhG-CSF 1,5,6,7 20 5.3215 0.2315 
Topical rhG-CSF 1,5,6,7 20 4.8905 0.1995 
Clotrimazole 1,5,6,7 20 3.5375 1.5525 . 
Combination 1,5,6,7 20 3.0355 2.0545 . 
Hydrocortisone 1,5,6,7 20 4.3525 0.7375 . 
. . . Ouant1tat1ve culture score s1gn1flcantly lower than untreated control group . 
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TABLE 13. Efficacy of therapeutic treatment with rhG-CSF in a murine 
model of vaginal candidiasis: Vaginal histopathology 
scores and microscopic remarks 
Treatment 
Box 172 
Systemic 
rhG-CSF 
Average 
Box 173 
Topical 
rhG-CSF 
Average 
Box 175 
Combo 
Therapy 
Average 
Box 176 
Hydrocort 
AveraQe 
. Key 
A 
B 
c 
D 
E 
A 
B 
c 
D 
E 
A 
B 
c 
D 
E 
A 
B 
c 
D 
E 
sev 
org 
inv 
epith 
mod 
Score 
3 
3 
3 
3 
2 
2.8 
3 
3 
1 
3 
3 
2.6 
2 
0 
0 
0 
1 
0.6 
3 
3 
2 
3 
3 
2.8 
Microscopic Remarks* 
sev org inv of epith 
sev org inv of epith 
sev org inv of epith 
sev org inv of epith 
mod inv of epith 
sev org inv of epith 
sev o~g_ inv of epith 
few org seen 
sev org inv of epith 
sev orQ inv of epith 
mod inv of epith 
no orQ seen 
no org seen 
no org seen 
few org seen 
sev org inv of epith 
sev orQ inv of epith 
mod org inv of epith 
sev orQ inv of epith 
sev org inv of epith 
severe 
organisms 
invasion 
epithelium 
moderate 
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TABLE 14. Efficacy of therapeutic treatment with rhG-CSF in a murine 
model of vaginal candidiasis: Statistical analysis of 
histopathology scores 
Analysis of Variance 
Source df ss MS F value p value 
treatment 3 17.200 5.733 11 .47 0.000 
error 16 8.000 0.500 
Total 19 25.200 
Mean Comparison 
Treatment Day N Mean so Significant 
Systemic rhG-CSF 10 5 2.8000 0.4472 
Topical rhG-CSF 10 5 2.6000 0.8944 
Hydrocortisone 10 5 2.8000 0.4472 
Combination 10 5 0.6000 0.8944 * 
* 
.. Histopathology score s1gn1f1cantly lower than control group score . 
TABLE 15. Validation of murine model of pulmonary aspergillosis: The 
effect of rhG-CSF treatment on WBC counts of normal and 
CPM immunosuppressed mice 
Box #Mice Immunosuppression Treatment Monitor 
449 48 None None WBC count 
Days -5,-3,-1 ,0 
450 48 Cyclophosphamide None WBC count 
200 mg/kg Days -5,-4,-3,-2,-1 ,0 
451 48 Cyclophosphamide rhG-CSF WBC count 
200 mg/kg 2.5 1.19 Days -5,-4,-3,-2,-1 ,0 
452 48 None rhG-CSF WBC count 
2.5 llg Days -5,-4,-3,-2,-1 ,0 
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TABLE 16. Validation of a murine model of pulmonary aspergillosis: WBC 
counts of normal and immunosuppressed mice treated with 
rhG-CSF 
WBC Count X 103 I ml 
Treatment Experiment Dav 
Group -5 -4 -3 -2 -1 0 
7.9 8.8 7.7 4.9 
3.9 6.8 7.4 4.1 
Box 449 5.7 6.4 5.4 4.9 
Control 6.8 5.7 6.4 5.0 
No Treatment 5.0 6.0 8.0 5.9 
5.1 7.3 5.9 5.9 
4 .3 7.6 7.3 7.3 
6.0 7.5 6.0 6.0 
Average WBC 5.6 NO 7.0 NO 6.9 5.5 
7.9 1.7 3.2 3.0 3.7 10.9 
3.9 2.3 1.8 3.0 2.5 17.5 
Box 450 5.7 3.2 1.8 4.6 2.2 19.4 
CPM& 6.8 3.6 3.0 2.6 4.2 17.7 
rhG-CSF 5.0 2.7 2.1 2.5 2.0 11 .3 
5.1 3.2 1.3 1.7 1.6 10.7 
4 .3 2.6 3.5 3.8 3.2 10.5 
6.0 1.9 3.1 9.6 
Average WBC 5.6 2.8 1.9 3.0 2.6 13.4 
7.9 2.4 1.9 3.6 2.2 1.7 
3.9 3.2 1.5 4.0 2.3 3.2 
Box 451 5.7 2.7 2.7 2.2 1.3 1.5 
CPM 6.8 2.6 1.4 2.3 1.8 2.6 
5.0 2.8 2.9 2.2 1.3 3.1 
5.1 2.5 1.5 1.6 1.6 3.4 
4.3 2.1 2.9 1.8 1.7 1.9 
6.0 1.9 1.9 3.0 1.1 3.6 
Average WBC 5.6 2.3 2.1 2.6 1.7 2.6 
7.9 3.8 6.6 13.8 21.7 22.3 
3.9 3.8 4.9 11.1 24.1 23.3 
Box 452 5.7 3.0 7.1 19.0 26.3 27.2 
rhG-CSF 6.8 7.5 4.7 12.7 15.7 16.9 
5.0 3.9 4.9 12.5 22.0 19.5 
5.1 6.5 3.7 12.1 17.2 41 .3 
4.3 3.8 5.6 14.4 21.6 12.0 
6.0 5.3 5.5 10.4 26.1 31.3 
Average WBC 5.6 5.2 5.4 13.3 21.8 23.0 
NO - No data collected on these days. 
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TABLE 17. Validation of a murine model of pulmonary aspergillosis: 
Source 
treatment 
error 
Total 
Treatment 
Control 
Statistical analysis of WBC count data from normal and CPM 
immunosuppressed mice treated with rhG-CSF from day 0 
Analysis of Variance 
df ss MS F value p value 
3 2243.9 748.0 29.75 0.000 
28 704.0 25.1 
31 2947.9 
Mean Comparison LSD=2.048 
Day Number Mean Difference Significant 
0 8 5.500 
CPM&rhG-CSF 0 8 13.450 7.950 . 
CPM 0 8 2.625 2.875 . 
rhG-CSF 0 8 24.225 18.725 . 
. . 
*WBC count srgnrfrcantly drfferent from untreated control group . 
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TABLE 18. Efficacy of prophylactic rhG-CSF treatment of pulmonary 
aspergillosis: Experimental design 
Challenge Daily 
Box I# Mice Concentrations Tx Treatment Comments 
439 10 1.0 X 108 CPM DsW Virulence 
orQ/ml control 
440 10 1.0 X 108 CPM rhG-CSF rhG-CSF 
orgJ ml 1.0 119 lo dose 
441 10 1.0 X 108 CPM rhG-CSF rhG-CSF 
orq/ml 2.5 119 hi dose 
442 10 1.0 X 108 CPM Lip AmB LipAmB 
orq/ml 5 119 lo dose 
443 10 1.0 X 108 CPM Lip AmB Lip AmB 
org/ml 10 119 mid dose 
444 10 1.0 X 108 CPM Lip AmB Lip AmB 
orQ / ml 20 119 hi dose 
445 10 1.0 X 108 CPM 20119 AmB AmB 
org/ml 
446 10 1.0 X 108 CPM 1.0 119 rhG-CSF & Combination 
orq/ml 10 119 LipAmB lo dose 
447 10 1.0 X 108 CPM 2.5 119 rhG-CSF & Combination 
orq/ml 10 119 LipAmB hi dose 
448 10 None CPM 2.5 1-19 rhG-CSF& Combination 
20 li<l LipAmB Toxicity 
TABLE 19. Efficacy of prophylactic rhG-CSF treatment of pulmonary 
aspergillosis: Mean survival time days 0 through 7 
Experiment Day 
Box Treatment -5 to-1 0 1 2 3 4 5 6 7 
439 Control 10 9t 9 7 2 2 2 2 2 
440 Lo rhG-CSF 10 10 10 10 10 10 10 10 10 
441 Hi rhG-CSF 10 10 10 10 10 10 10 10 9 
442 Lo Lip AmB 10 10 10 10 10 10 10 10 10 
443 Mid lip AmB 10 10 10 10 9 8 8 8 8 
444 Hi LipAmB 9. 8t 8 8 6 5 5 5 5 
445 AmB 10 10 10 10 9 9 9 9 9 
446 Lo Combo 10 10 10 10 10 10 10 10 10 
447 Hi Combo 10 10 10 10 10 10 10 10 10 
448 Toxicity 10 10 10 10 10 10 10 10 10 
*Dosing death tAnesthetic death 
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MST 
2.9 
7.0 
6.9 
7.0 
6.1 
5.3 
6.5 
7.0 
7.0 
7.0 
TABLE 20. Efficacy of prophylactic rhG-CSF treatment of pulmonary 
aspergillosis: Average clinical sign scores and weights 
Exp Box 439 Control Exp Box 440 Lo rhG-CSF 
Day HC POS ACT Wt(g) Day HC POS ACT Wt(g) 
0 0 0 0 22 .7 0 0 0 0 23.4 
1 1 .5 1.3 1.7 20.4 1 1.6 1.1 1.2 20.7 
2 1.5 2 .1 2.7 2 1.8 1.4 1.4 
3 2.0 2.0 2.0 3 1.8 1 .5 1.5 
4 2.0 2.0 1.5 19.6 4 1.9 1.6 1.4 22.9 
5 2.5 2 .0 1.5 5 1.7 1.5 1.4 
6 2 .5 2 .0 1.5 20.2 6 1.6 1.6 1.2 23.8 
7 2 .5 2.5 1.5 7 1.7 1.4 1.2 
8 2.5 2.5 1 .5 20.2 8 1.6 1.4 1.2 24.9 
9 2.0 2.5 2.0 9 1.4 1.3 1.2 
10 2 .0 2.0 2.0 10 1.2 1.2 1.0 
11 2.0 1.5 1.0 20.9 11 1.2 1.2 0 .8 25.5 
12 2.0 1.5 1.0 12 1.0 1.0 0.8 
13 2.0 1.5 1.0 21.1 13 0.9 0.5 0 .2 25.9 
14 2 .0 1.0 0.5 14 0.6 0 0 
15 2.0 0.5 0 .5 21.8 15 0.6 0 0 26.0 
16 2.0 0.5 0 .5 16 0.8 0 0 
17 2 .0 0.5 0.5 17 0.7 0 0 
18 2.0 0.5 0.5 23.2 18 0 .7 0 0 27.1 
19 2.0 0.5 0 .5 19 0 .6 0 0 
20 2 .0 0.5 0 .5 24.0 20 0 .6 0 0 27.5 
Ave 1.8 1.3 1.0 21.4 Ave 1.1 0.8 0 .7 24.8 
Exp Box 441 Hi rhG-CSF Exp Box 442 Lo Lio AmB 
Day HC POS ACT WI( g) Day HC POS ACT Wt(g) 
0 0 0 0 23.2 0 0 0 0 24.1 
1 1.5 1.2 1.5 20.5 1 1.5 1.6 1.5 20.9 
2 2.3 1.6 1.7 2 2.3 1.8 1.8 
3 1.9 1.3 1.1 3 1.9 1 .7 1.5 
4 2.0 1.6 1.0 22.1 4 2 .0 1.5 1.5 19.1 
5 2 .0 1.9 1.0 5 2 .0 1.6 1.3 
6 2 .0 1.8 1.1 23.1 6 2.0 1.5 1.4 20.4 
7 1.7 1.6 1.1 7 1.7 1.4 1.2 
8 1.4 1.6 1 .0 24.9 8 1.4 1.3 1.0 22.2 
9 1.4 1.7 0 .8 9 1.4 1.3 0.8 
10 1.3 1.2 0 .8 10 1 .3 1.1 0 .7 
11 1.3 1.0 0 .6 24.9 11 1.3 0.9 0 .8 23.0 
12 1.3 1.0 0.4 12 1.3 1.0 0.8 
13 1.2 0.8 0.2 25.5 13 1.2 1.0 0 .2 23.5 
14 0.9 0.7 0.1 14 0 .9 0.4 0 .1 
15 0.8 0.1 0 27.4 15 0.8 0.2 0 24.9 
16 0.8 0.1 0 16 0.8 0.2 0 
17 0.8 0 0 17 0.8 0 .1 0 
18 0.6 0 0 27.4 18 0.8 0 0 26.0 
19 0.6 0 0 19 0.8 0 0 
20 0 .6 0 0 27.9 20 0.8 0 0 26.8 
Ave 1.3 0.9 0.6 24.7 Ave 1.4 0.9 0 .7 23.1 
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TABLE 20. Continued 
Exp Box 443 Mid Lip AmB Exp Box 444 Hi Lip AmB 
Day HC POS ACT Wt(ol Day HC POS ACT Wt(q] 
0 0 0 0 23.2 0 0 0 0 24.2 
1 1 .8 1.4 1.5 21 .7 1 1.6 1.6 1.8 22.0 
2 2.1 1.7 1.8 2 2.2 1.8 1.9 
3 2 .1 1.2 1.9 3 2.3 2.2 1.8 
4 2.1 1.2 1 .8 20.0 4 2.4 2.0 1.6 19.2 
5 2.1 1.3 1.5 5 2.6 2 .2 1.8 
6 2 .1 1.2 1.5 20.2 6 2 .6 1.8 1.6 20.6 
7 2.1 1.2 1.3 7 2.4 2 .0 1.8 
8 2 .1 1.2 1.4 20.6 8 2 .0 1.8 1.4 21.1 
9 1.8 1.2 1.2 9 2.0 1.8 1.4 
10 1.8 1.0 1.0 10 2 .0 1.8 1.4 
11 1.8 0.8 0 .8 22.0 11 2.0 1.8 1 .4 22.7 
12 1.5 0.6 0.7 12 2.0 1.8 1.4 
13 1.1 0.4 0.8 22.6 13 1.4 1 .4 1.0 23.4 
14 0.9 0.2 0.4 14 1.4 1.0 0.4 
15 0.9 0.1 0 .1 23.5 15 1.4 0.4 0.2 24.0 
16 0 .9 0 0.1 16 1.6 0.2 0.2 
17 0.9 0 0 17 1.6 0.2 0 .2 
18 0.8 0 0 23.9 18 1.2 0.2 0 .2 25.1 
19 0 .8 0 0 19 1 .2 0 .2 0.2 
20 0.8 0 0 24.5 20 1.2 0.2 0.2 25.1 
Ave 1.6 0.8 0.4 22 .2 Ave 1.8 1.2 1.0 22.7 
Exp Box 445AmB Exp Box 446 Lo Combination 
Day HC POS ACT Wtfol Dav HC POS ACT Wt{g) 
0 0 0 0 24.4 0 0 0 0 24.0 
1 1.9 1.4 1.4 22 .2 1 1.6 1.3 1.0 21.6 
2 2 .0 1.7 1.7 2 1.6 1.4 1.3 
3 1.9 1.2 1.1 3 1.9 1.2 1.1 
4 2 .0 1.2 1.1 20.7 4 2 .0 1.7 1.4 22.1 
5 2 .2 1.3 1.1 5 1.9 1.7 1.4 
6 2.0 1.2 1.0 21.9 6 1.7 1.8 1.2 23.2 
7 1.8 1.2 1.0 7 1 .5 1.6 1.1 
8 1.4 1.2 1.0 22 .8 8 1.5 1.2 1.0 24.5 
9 1.4 1.2 0 .8 9 1.3 1.4 0.9 
10 1.3 0.9 0.8 10 1.1 1.2 0.6 
11 1.3 0.8 0.6 23.9 11 1 .1 0.9 0.5 25.0 
12 1.1 0.6 0.4 12 1.1 0.8 0 .5 
13 1.0 0 .4 0.2 25.3 13 1.0 0 .6 0.3 25.3 
14 0 .7 0.2 0.1 14 0.7 0 .4 0 .1 
15 0.6 0.1 0 25 .8 15 0.7 0 .1 0.1 25.3 
16 0 .6 0 0 16 0.7 0.1 0 
17 0 .6 0 0 17 0.6 0 0 
18 0.6 0 0 27.4 18 0.5 0 0 26.2 
19 0.6 0 0 19 0.5 0 0 
20 0.6 0 0 27.8 20 0 .4 0 0 27.2 
Ave 1.2 0.7 0.6 24.2 Ave 1.1 0.8 0.6 24.4 
TABLE 20. Continued 
Exp Box 447 Hi Combination Exp Box 448 Toxicit 
Day HC POS ACT Wt(q) Day HC POS ACT Wt(q) 
0 0 0 0 23.3 0 0 0 0 23.6 
1 2.0 1.0 1.1 20.8 1 1.3 1.0 1.0 21.3 
2 2.1 1.3 1.3 21.6 2 1.0 1.0 1.0 
3 2.3 1.3 1.3 23.3 3 1.3 1.0 1.0 
4 2.2 1.5 1.1 21.6 4 1.7 1.3 1.1 23.5 
5 2.1 1.5 1.2 5 1.6 1.2 1.1 
6 1.9 1.2 1.3 23.3 6 1.7 1.4 1.1 23.6 
7 1.8 1.3 1.2 7 1.5 1.3 0.9 
8 1.7 1.5 1.0 24.4 8 1.2 1.1 0.6 25.3 
9 1.4 1.4 0.9 9 1.1 1.0 0.3 
10 1.2 1.2 0.8 10 0.7 1.1 0.4 
11 1.2 0.9 0.8 24.9 11 0 .7 1.0 0.4 26.3 
12 1.3 0.9 0.7 12 0.7 0.8 0.4 
13 1.1 0.9 0.2 25.1 13 0.6 0.1 0 26.3 
14 1.0 0.5 0.1 14 0.6 0 0 
15 0.9 0.3 0.1 25.6 15 0.6 0 0 26.9 
16 0.9 0.1 0 16 0.6 0 0 
17 0.9 0.1 0 17 0 .5 0 0 
18 1.0 0.1 0 27 .8 18 0.4 0 0 28.0 
19 1.0 0.1 0 19 0.4 0 0 
20 1.0 0.1 0 27.6 20 0.4 0 0 28.2 
Ave 1.4 0.8 0.6 24.4 Ave 0.9 0.6 0.4 25.3 
TABLE 21 . Efficacy of prophylactic rhG-CSF treatment of pulmonary 
aspergillosis: Pre challenge average animal weights 
Average Weight in Grams 
Box Treatment -6 -3 -1 
439 Control 22.1 22.7 22.7 
440 Lo rhG-CSF 21.6 22.9 23.4 
441 Hi rhG-CSF 21 .8 23.3 23.2 
442 Lo Lip AmB 22.4 24.0 24.1 
443 Mid Lip AmB 22.3 22.9 23.2 
444 Hi liJJAmB 23.1 23.6 24.2 
445 AmB 23.4 24.1 24.4 
446 Lo Combo 22.5 23.3 24.0 
447 Hi Combo 21.9 23.3 23.3 
448 Toxicity 21.8 22.7 23.6 
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TABLE 22. Efficacy of prophylactic rhG-CSF treatment of pulmonary 
aspergillosis: Statistical analysis of animal weight data 
Analysis of Variance 
Source df ss MS F value p value 
treatment 8 1806.7 225.8 16.58 0.000 
error 1570 21390.7 13.6 
Total 1578 23197.4 
Mean Comparison 
Treatment N Mean SD p value Significant 
Control 61 21 .130 4.456 
Lo rhG-CSF 210 24.794 3.518 0.0007 * 
Hi rhG-CSF 196 24.477 3 .107 0.0028 * 
Lo LipAmB 210 23.042 3.665 0.0870 
Mid Lip AmB 175 22 .003 4.382 0.2500 
Hi Lip AmB 115 22.472 3.707 0.1100 
AmB 192 23.934 4 .282 0.0066 * 
Lo Comb 210 24.475 3.174 0.0006 * 
Hi Comb 210 24.484 3.393 0.0031 * 
* 
. . Mean we1ght s1gmf1cantly higher than untreated control group. 
TABLE 23. Efficacy of prophylactic rhG-CSF treatment of pulmonary 
aspergillosis: Statistical analysis of haircoat scores 
Analysis of Variance 
Source df ss MS F value p value 
treatment 8 64.990 8.124 10.57 0.000 
error 1570 1206.121 0.768 
Total 1578 1271 .111 
Mean Comparison 
Treatment Number Mean SD Significant 
Control 61 1.7869 1.0972 
Lo rhG-CSF 210 1.1084 0.7998 * 
Hi rhG-CSF 196 1.2806 0.8151 * 
Lo Lip AmB 210 1.4429 0.0119 * 
Mid Lip AmB 175 1.4400 1.0089 * 
Hi Lip AmB 115 1.7826 1.0241 
AmB 192 1.2031 0.8533 * 
Lo Comb 210 1.1190 0.7641 * 
Hi Comb 210 1.3714 0.8156 * 
* 
. . Mean ha1rcoat score Significantly lower than untreated control group. 
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TABLE 24. Efficacy of prophylactic rhG-CSF treatment of pulmonary 
aspergillosis: Statistical analysis of posture scores 
Analvsis of Variance 
Source df ss MS F value p value 
treatment 8 39.882 4 .985 7.16 0.000 
error 1570 1092.528 0.690 
Total 1578 1132.409 
Mean Comparison 
Treatment Number Mean so Siqnificant 
Control 61 1.3115 1.0574 
Lo rhG-CSF 210 0.8619 0.7671 * 
Hi rhG-CSF 196 0.9184 0.8311 * 
Lo Lip AmB 210 0.9714 0.8467 * 
Mid Lip AmB 175 1.0171 0 .9000 
Hi LioAmB 115 1.2522 1.0416 
AmB 192 0.7135 0.7563 * 
Lo Comb 210 0.8238 0.8140 * 
Hi Comb 210 0.7107 0.7107 * 
.. 
*Mean posture score s1gn1f1cantly lower than untreated control group. 
TABLE 25. Efficacy of prophylactic rhG-CSF treatment of pulmonary 
aspergillosis: Statistical analysis of activity level scores 
Analysis of Variance 
Source df ss MS F value p value 
treatment 8 39.349 4.919 8.87 0.000 
error 1570 871.053 0.555 
Total 1578 910.402 
Mean Comparison 
Treatment Number Mean so Significant 
Control 61 1.1475 0.9280 
Lo rhG-CSF 210 0.6952 0.6934 * 
Hi rhG-CSF 196 0.6786 0.7116 * 
Lo LTD AmB 210 0.7714 0 .7419 * 
Mid Lip AmB 175 0.9086 0.8923 
Hi Lip AmB 115 1.0609 0.9486 
AmB 192 0.5990 0.6715 * 
Lo Comb 210 0.5952 0 .6511 * 
Hi Comb 210 0.6238 0 .6536 * 
. . . . 
*Mean act1v1ty level score s1gn1f1cantly lower than untreated control group . 
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TABLE 26. Efficacy of prophylactic rhG-CSF treatment of pulmonary 
aspergillosis: Gross pathology and histopathology scores, 
and microscopic remarks 
Box Lung Body LBWR GPS HPS Microscopic 
wt (q) wt (q) Remarks 
Box 439 A 0.29 18.8 .015 3 3 sev inv 
Control J 0.18 29.1 .006 0 0 few orq seen 
averaqe .011 1.5 1.5 
A 0.22 32.1 .007 0 0 no orq seen 
B 0.20 29.2 .007 0 0 no orq, mild con 
c 0.21 25.0 .008 0 0 few org, mild con 
D 0.30 29.5 .010 2 1 few orq, mild con 
Box 440 E 0.23 30.1 .008 0 1 mild con 
Lo rhG-CSF F 0.15 26.4 .006 0 3 sev inv 
G 0.20 29.4 .007 0 0 no org, mild con 
H 0.22 28.0 .008 1 0 no orq, mild con 
I 0.27 24.6 .010 2 1 few orq, mild con 
J 0.37 20.6 .018 2 3 sev wo, sev con 
average .010 0.7 0.9 
A 0.19 26.1 .007 0 0 no orq seen 
B 0.26 29.7 .009 0 2 mod woorq 
c 0.21 28.6 .007 0 2 mod wo org 
Box 441 D 0.24 29.0 .008 0 0 no orq seen 
Hi rhG-CSF E 0.24 25.0 .010 0 1 mildwoorq 
F 0.24 30.2 .008 0 0 few orq seen 
G 0.28 31.2 .009 1 0 mild con 
I 0.31 26.8 .012 1 2 mod wo oro 
J 0.23 24.8 .009 1 1 mildwoorg 
averaqe .009 0.3 0.8 
A 0.23 29.1 .008 1 3 sev inv 
B 0.40 24.7 .016 3 3 sev con, mod org, wo 
c 0.21 30.0 .007 0 3 sev con, mod org 
D 0.19 25.7 .007 0 1 few orq seen 
Box 442 E 0.24 26 .3 .009 0 1 few orq seen 
Lo Lip AmB F 0.31 25.1 .012 0 1 few orq seen 
G 0.24 28.6 .008 1 1 few oro seen 
H 0.31 23.1 .013 3 3 sev con 
I 0.23 31.0 .007 0 1 mildwo 
J 0.25 24.2 .010 0 2 modwo 
averaqe .010 0.8 1.9 
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TABLE 26. Continued 
Box Lung Body LBWR GPS HPS Microscopic 
wt (g) wt <9l Remarks 
A 0.17 24.5 .007 0 0 no ora seen 
B 0.41 21.3 0.19 3 3 mod inv, mod con 
c 0.25 27.5 .009 1 2 mod con 
Box 443 D 0.23 27.2 .008 0 2 mod inv, mod con 
Mid Lip AmB E 0.26 26.4 .010 0 2 mod con, mod wo 
F 0.30 24.1 .012 3 3 sev inv, mod con nee 
G 0.23 30.4 .008 0 2 wo, mod con, nee 
H 0.38 14.9 .026 3 3 sev inv, mild con, nee 
average .012 1.3 2.1 
c 0.34 29.5 .011 3 3 mod con, mod inv 
D 0.78 20.3 .038 3 3 sev con, sev inv, nee 
Box 444 F 0.18 26.6 .007 0 2 mod inv 
Hi Lip AmB H 0.25 25.8 .010 0 2 mod inv, mod con 
J 0.27 23.5 .011 0 2 mod con , nee 
average .015 1.2 2.4 
A 0.28 34.0 .008 0 2 mild con 
B 0.27 24.3 .011 2 3 sev con, inv, nee 
c 0.23 28.8 .008 0 1 mildwoora 
Box 445 D 0.52 22.1 .023 3 3 sev con, nee, sev inv 
Hi rhG-CSF E 0.22 30.6 .007 0 1 foci of wo org 
F 0.26 29.0 .009 2 3 mod con, nee, sev inv 
G 0.22 28.7 .008 0 1 few org, mild wo 
H 0.45 25.6 .018 3 3 sev con, nee 
I 0.33 26.8 .012 0 2 mild con few ora 
averaae .012 1.1 2.1 
A 0.25 25.5 .010 0 1 few org seen 
B 0.29 28.4 .010 0 2 mildwoorg 
c 0.23 28.4 .008 0 2 modwo org 
D 0.22 27.7 .008 0 2 mild con, mod wo 
Box 446 E 0.20 26.2 .008 0 1 mild con, few ora 
Lo Combination F 0.23 25.1 .009 0 1 fewwoora 
G 0.31 25.2 .012 0 1 foci of wo org_ 
H 0.25 24.4 .010 1 3 mod con nee 
I 0.20 29.5 .007 0 0 no org seen 
J 0.20 31.1 .006 0 0 no ora seen 
averaae .008 0.1 1.3 
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TABLE 26. Continued 
Box I Treatment Lung Body LBWR GPS HPS Microscopic 
wt (g) wt(g) Remarks 
A 0.20 25 .7 .008 0 3 sev con, nee 
B 0.43 27.3 .016 1 2 mod wo, nee 
c 0.20 31 .3 .006 0 1 mild con 
0 0.22 30 .6 .007 1 1 mild con, few oro 
Box 447 E 0.20 28.9 .007 0 1 foci of wo, mild con 
Hi Combination F 0.34 29.3 .012 1 2 mod con, sev wo orq 
G 0.34 23.4 .015 0 1 mild con, few oro 
H 0.23 28.2 .008 0 0 mild con, few org 
I 0.20 25 .3 .008 1 1 mod con, few org 
J 0.21 26 .1 .008 1 2 mild con, few orq 
average .010 0.5 1.2 
A 0.17 26.1 .007 0 
B 0.19 28.0 .007 0 
c 0.19 27.7 .007 0 
0 0.18 31.0 .006 0 
Box 448 E 0.20 29 .3 .007 0 
Toxicity F 0.20 25 .0 .008 1 
Control G 0.20 29 .6 .007 0 
H 0.21 29.5 .007 0 
I 0.18 27.9 .006 0 
J 0.19 27.9 .007 0 
.007 0.1 Nl Nl 
Nl = noninfected an1mals, no sect1ons taken . 
*Key sev severe 
inv invasion 
org organisms 
con consolidation 
wo wall ing off 
mod moderate 
nee necrosis 
TABLE 27. Efficacy of prophylactic rhG-CSF treatment of pulmonary 
aspergillosis: Statistical analysis of gross pathology 
scores 
Analysis of Variance 
Source df ss MS F value p value 
treatment 8 13.03 1.63 1.54 0.164 
error 60 63.58 1.06 
Total 68 76.61 
TABLE 28. Efficacy of prophylactic rhG-CSF treatment of pulmonary 
aspergillosis: Statistical analysis of histopathology 
scores 
Analysis of Variance 
Source df ss MS F value p value 
treatment 8 15.898 1.987 2.01 0.060 
error 60 59.319 0.989 
Total 68 75.217 
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